Core Viewpoint - North American Construction (NOA) has shown a significant price increase of 11.1% over the past four weeks, with a mean price target of $25.70 indicating a potential upside of 51.1% from its current price of $17.01 [1] Price Targets and Analyst Consensus - The average price target for NOA ranges from a low of $19.46 to a high of $31.68, with a standard deviation of $3.99, suggesting a variability in analyst estimates [2] - The lowest estimate indicates a 14.4% increase, while the highest suggests an 86.2% upside [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Optimism - Analysts are optimistic about NOA's earnings prospects, as indicated by a trend of upward revisions in earnings estimates [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 1.3%, with one estimate moving higher and no negative revisions [12] - NOA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are often sought after, they can mislead investors, as empirical research shows they rarely indicate actual stock price movements [7] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8] - Investors should treat price targets with skepticism and not rely solely on them for investment decisions [10]

Core Viewpoint - Olema Pharmaceuticals, Inc. (OLMA) shows significant upside potential with a mean price target of $24.71, indicating a 386.4% increase from the current price of $5.08 [1] Price Targets - The average price target consists of seven estimates ranging from a low of $18 to a high of $30, with a standard deviation of $4.64, suggesting variability in analyst opinions [2] - The lowest estimate indicates a potential increase of 254.3%, while the highest suggests a 490.6% upside [2] - A low standard deviation indicates a higher agreement among analysts regarding price movement [9] Analyst Sentiment - Analysts are optimistic about OLMA's earnings prospects, as indicated by a positive trend in earnings estimate revisions [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 25.4%, with five estimates moving higher and no negative revisions [12] Zacks Rank - OLMA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for upside [13]

Core Viewpoint - SkyWater Technology, Inc. (SKYT) shows significant potential for upside, with a mean price target of $11 indicating a 35% upside from its current price of $8.15, following a 23.7% gain over the past four weeks [1]. Price Targets and Analyst Consensus - The average price targets from analysts range from a low of $8 to a high of $12, with a standard deviation of $1.73, indicating variability in estimates. The lowest estimate suggests a decline of 1.8%, while the highest points to a 47.2% upside [2]. - A low standard deviation among price targets suggests strong agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9]. Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding SKYT's earnings prospects, as indicated by a positive trend in earnings estimate revisions. This trend has a strong correlation with near-term stock price movements [11]. - Over the last 30 days, two earnings estimates for SKYT have been revised upward, leading to a 20.8% increase in the Zacks Consensus Estimate [12]. Zacks Rank and Investment Potential - SKYT holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, which further supports its potential for upside [13].

Core Viewpoint - Encore Capital Group (ECPG) has shown a significant price increase of 38.2% over the past four weeks, with a mean price target of $58.50 indicating a potential upside of 44.4% from the current price of $40.51 [1] Price Targets and Analyst Consensus - The average price target for ECPG ranges from a low of $55 to a high of $66, with a standard deviation of $5.07, suggesting a relatively high agreement among analysts [2] - The lowest estimate indicates a potential increase of 35.8%, while the most optimistic estimate suggests a 62.9% upside [2] - Analysts' price targets should be approached with caution, as they may not always accurately reflect future stock movements [3][7] Earnings Estimates and Analyst Optimism - Analysts have shown strong agreement in revising ECPG's earnings estimates higher, which is a positive indicator for potential stock upside [4][11] - The Zacks Consensus Estimate for the current year has increased by 11.8% over the past month, with three estimates revised upward and no negative revisions [12] - ECPG holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Investment Potential - While the consensus price target may not be a reliable indicator of the extent of ECPG's potential gains, the direction implied by these targets appears to be a useful guide for further research [13]

Core Viewpoint - Amneal Pharmaceuticals (AMRX) has seen a 7% increase in share price over the past four weeks, closing at $7.46, with analysts suggesting a potential upside of 54.2% based on a mean price target of $11.50 [1] Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $0.58, indicating a range where the lowest estimate is $11 (47.5% increase) and the highest is $12 (60.9% increase) [2] - A low standard deviation suggests a strong agreement among analysts regarding the price targets, which can be a useful indicator for further research [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about AMRX's earnings prospects, with a positive trend in earnings estimate revisions, which historically correlates with stock price movements [11] - The Zacks Consensus Estimate for the current year has risen by 5% over the past month, with three estimates increasing and no negative revisions [12] - AMRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13]

Group 1 - Pfizer (PFE) closed at $22.79, with a 1.3% gain over the past four weeks, and a mean price target of $28.52 indicating a 25.1% upside potential [1] - The average of 21 short-term price targets ranges from $23 to $35, with a standard deviation of $3.16, suggesting variability in analyst estimates [2] - Analysts have shown increasing optimism about PFE's earnings prospects, with a 3.2% increase in the Zacks Consensus Estimate for the current year and no negative revisions [12][11] Group 2 - The Zacks Rank for PFE is 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - A tight clustering of price targets, indicated by a low standard deviation, suggests a high degree of agreement among analysts regarding the stock's price movement [9] - While price targets can be misleading, the direction implied by them may serve as a useful guide for further research into the stock's potential [10][7]

Core Viewpoint - Edison International (EIX) shows potential for upside with a mean price target of $69.97, indicating a 27.5% increase from the current price of $54.88 [1] Price Targets and Analyst Consensus - The average price target consists of 16 estimates ranging from a low of $50.50 to a high of $86, with a standard deviation of $10.02, suggesting variability in analyst predictions [2] - The lowest estimate indicates an 8% decline, while the highest suggests a 56.7% upside, highlighting the range of opinions among analysts [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement direction, which can be a starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about EIX's earnings prospects, as evidenced by a trend of higher EPS estimate revisions [11] - The Zacks Consensus Estimate for the current year has risen by 2% over the past month, with three estimates increasing and one decreasing [12] - EIX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13]

Group 1 - The core viewpoint is that Triple Flag Precious Metals (TFPM) has significant upside potential, with a mean price target of $27.81 indicating a 32.8% increase from its current price of $20.94 [1] - Analysts have set 11 short-term price targets for TFPM, ranging from a low of $19 to a high of $36.50, with a standard deviation of $6.24, suggesting variability in estimates [2] - The consensus among analysts indicates that TFPM is expected to report better earnings than previously estimated, which historically correlates with stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for TFPM's current year earnings has increased by 12.3% over the past month, with five estimates revised upward and no negative revisions [12] - TFPM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] - While price targets are often viewed skeptically, the direction implied by these targets can serve as a useful guide for potential stock movements [10][11]

Shares of Lam Research (LRCX) have gained 10% over the past four weeks to close the last trading session at $71.73, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $90.93 indicates a potential upside of 26.8%.The mean estimate comprises 27 short-term price targets with a standard deviation of $12.03. While the lowest estimate of $70 indicates a 2.4% decline from the current pric ...

Synovus Financial (SNV) closed the last trading session at $44.10, gaining 10% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $55.56 indicates a 26% upside potential.The mean estimate comprises 16 short-term price targets with a standard deviation of $5.85. While the lowest estimate of $46 indicates a 4.3% increase from the current price level, the most optimistic analyst expects ...